Auspex Pharmaceuticals will conduct initial public offering of stock

Deal funds clinical trials and development, general corporate purposes

By Devika Patel

Knoxville, Tenn., Dec. 20 - Auspex Pharmaceuticals, Inc. will price an initial public sale of its common stock with a 30-day greenshoe, according to a Form S-1 filed Friday with the Securities and Exchange Commission.

Stifel and BMO Capital Markets are the joint bookrunners, and Baird, William Blair and Ladenburg Thalmann & Co. Inc. are the co-managers.

Proceeds will be used for clinical development and clinical trials, commercialization, research and development, working capital and other general corporate purposes.

The biopharmaceutical company is based in San Diego. It expects its shares will trade on the Nasdaq under the symbol "ASPX."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.